ArticleJournal of oral biology and craniofacial research
Increased expression of mitochondrial enzyme MTHFD2 associated with clinicopathological features and prognosis of oral squamous cell carcinoma.
Article in Journal of oral biology and craniofacial research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study investigated the expression profile of MTHFD2 at both transcript and protein levels in oral squamous cell carcinoma (OSCC). In addition, its association with clinicopathological parameters, patient survival, and immune-related features was systematically evaluated. Methods: Publicly available transcriptomic data from The Cancer Genome Atlas were analyzed to assess MTHFD2 expression in OSCC, followed by experimental validation in an independent cohort of 42 OSCC patients. Quantitative real-time PCR was employed to validate Results: Both mRNA and protein expression levels of MTHFD2 were significantly elevated in OSCC tissues compared with adjacent non-tumor counterparts. Increased MTHFD2 expression was significantly associated with adverse clinicopathological features and poorer survival outcomes in OSCC patients. Protein interaction network analysis revealed that MTHFD2 interacts with multiple oncogenic signaling pathways. Functional enrichment analyses indicated a strong link between MTHFD2-associated networks and biological processes relevant to OSCC initiation and progression. Conclusions: Elevated MTHFD2 expression is closely linked to aggressive disease behavior and unfavorable prognosis in OSCC. Its integration within oncogenic signaling pathways and interaction with critical cancer-associated proteins suggest that MTHFD2 may serve as a potential biomarker associated with disease progression. Further functional studies are required to determine its biological and clinical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.